Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats

Circulation Journal

Volumn 77, Issue 6, 2013, Pages 1474-1481

  Yasuoka, Suguru ^a   Kai, Hisashi ^a   Kajimoto, Hidemi ^c   Kudo, Hiroshi ^a   Takayama, Narimasa ^a   Anegawa, Takahiro ^b   Koga, Mitsuhisa ^e   Miyamoto, Takanobu ^c   Mifune, Hiroharu ^d   Kage, Masayoshi ^f   Hirooka, Yoshitaka ^g   Imaizumi, Tsutomu ^a  

^a Department of Internal Medicine Division of Cardio Vascular Medicine ^*  (Japan)

^b Cardiovascular Research Institute   (Japan)

^c Institute of Animal Experimentation   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e FUKUOKA UNIVERSITY   (Japan)

^f KURUME UNIVERSITY HOSPITAL   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

Author keywords

Blood pressure variability; Cardiac hypertrophy; Fibrosis; Inflammation; Mineralocorticoids

Indexed keywords

ALDOSTERONE; EPLERENONE; HYDROCORTISONE; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; P21 ACTIVATED KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDITIS; CELL INFILTRATION; ECHOCARDIOGRAPHY; HEART DENERVATION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEMODYNAMIC MONITORING; HYPERTENSION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; MORPHOMETRICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHAM PROCEDURE;

ACTIVE TRANSPORT, CELL NUCLEUS; ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CELL NUCLEUS; HUMANS; HYDROCORTISONE; HYPERTENSION; MACROPHAGES; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MUSCLE PROTEINS; MYOCARDITIS; MYOCARDIUM; P21-ACTIVATED KINASES; PHOSPHORYLATION; RATS; RATS, INBRED SHR; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; VENTRICULAR REMODELING;

EID: 84878260509     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1253     Document Type: Article

References (40)

1. Zia AA, Kamalov G, Newman KP, McGee JE, Bhattacharya SK, Ahokas RA, et al. From aldosteronism to oxidative stress: The role of excessive intracellular calcium accumulation. Hypertens Res 2010; 33: 1091-1101.
2. Gavras H, Brunner HR, Laragh JH, Vaughan ED Jr, Koss M, Cote LJ, et al. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: Role of renin and sodium in vascular changes. Circ Res 1975; 36: 300-309.
3. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46: 1227-1235.
4. Schiffrin EL. Effects of aldosterone on tha vasculature. Hypertension 2006; 47: 312-318.
5. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Min-eralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-458.
6. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, et al. Aldosterone induces a vascular infammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810.
7. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: Role of oxidative stress. Hypertension 2007; 50: 877-883.
8. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987; 5: 93-98.
9. Nair AP, Timoh T, Fuster V. Contemporary medical management of systolic heart failure. Circ J 2012; 76: 268-277.
10. Hirai Y, Geleijnse JM, Adachi H, Imaizumi T, Kromhout D. Systolic blood pressure predicts cardiovascular mortality in a farming but not in a fishing community: A 40-year follow up of the Japanese cohorts of the seven countries study. Circ J 2011; 75: 1890-1896.
11. Sega R, Corrao G, Bombelli M, Beltrame L, Facchetti R, Grassi G, et al. Blood pressure variability and organ damage in a general population: Results from the PAMELA study (Pressioni Arteriose Moni-torate E Loro Associazioni). Hypertension 2002; 39: 710-714.
12. Tatasciore A, Zimarino M, Renda G, Zurro M, Soccio M, Prontera C, et al. Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. Hypertens Res 2008; 31: 2137-2146.
13. Kudo H, Kai H, Kajimoto H, Koga M, Takayama N, Mori T, et al. Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. Hypertension 2009; 54: 832-838.
14. Takayama N, Kai H, Kudo H, Yasuoka S, Mori T, Anegawa T, et al. Simvastatin prevents large blood pressure variability-induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways. Hypertens Res 2011; 34: 341-347.
15. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, et al. Transforming growth factor-/? function blocking prevents myocardial fbrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106: 130-135.
16. Kai H, Muraishi A, Sugiu Y, Nishi H, Seki Y, Kuwahara F, et al. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res 1998; 83: 594-601.
17. Kuwahara F, Kai H, Tokuda K, Niiyama H, Tahara N, Kusaba K, et al. Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling. Hypertension 2003; 41: 819-823.
18. Kuwahara F, Kai H, Tokuda K, Shibata R, Kusaba K, Tahara N, et al. Hypoxia-inducible factor-1a/vascular endothelial growth factor pathway for adventitial vasa vasorum formation in hypertensive rat aorta. Hypertension 2002; 39: 46-50.
19. Kai H, Kuwahara F, Tokuda K, Shibata R, Kusaba K, Niiyama H, et al. Coexistence of hypercholesterolemia and hypertension impairs adventitial vascularization. Hypertension 2002; 39: 455-459.
20. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, et al. Hypertensive myocardial fibrosis and diastolic dysfunction: Another model of inflammation. Hypertension 2004; 43: 739-745.
21. Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H, et al. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 2004; 43: 499-503.
22. Mori T, Kai H, Kajimoto H, Koga M, Kudo H, Takayama N, et al. Enhanced cardiac inflammation and fibrosis in ovariectomized hypertensive rats: A possible mechanism of diastolic dysfunction in postmenopausal women. Hypertens Res 2011; 34: 496-502.
23. Takemiya K, Kai H, Yasukawa H, Tahara N, Imaizumi T. Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats. Basic Res Cardiol 2010; 105: 409-417.
24. Kai H, Griendling KK, Lassegue B, Ollerenshaw JD, Runge MS, Alexander RW. Agonist-induced phosphorylation of the vascular type 1 angiotensin II receptors. Hypertension 1994; 24: 523-527.
25. Kusaba K, Kai H, Koga M, Takayama N, Ikeda A, Yasukawa H, et al. Inhibition of intrinsic interferon- y function prevents neointima formation after balloon injury. Hypertension 2007; 49: 909-915.
26. Koga M, Kai H, Yasukawa H, Yamamoto T, Kawai Y, Kato S, et al. Inhibition of progression and stabilization of plaques by therapeutic interferon-y function blocking in ApoE-KO mice. Circ Res 2007; 101: 348-356.
27. Tahara N, Kai H, Niiyama H, Mori T, Sugi Y, Takayama N, et al. Repeated gene transfers of naked prostacyclin synthase plasmid into skeletal muscles attenuate monocrotaline-induced pulmonary hypertension and prolong survival in rats. Human Gene Ther 2004; 15: 1270-1278.
28. Kai H, Griendling KK, Lassègue B, Fukui T, Minieri CA, Alexander RW. Prolonged exposure to agonist results in a reduction in the levels of the Gq/G11 a-subunit in cultured vascular smooth muscle cells. Mol Pharmacol 1996; 49: 96-104.
29. Echeverría PC, Mazaira G, Erlejman A, Gomez-Sanchez C, Piwien Pilipuk G, Galigniana MD. Nuclear import of the glucocorticoid re-ceptor-hsp90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin beta. Mol Cell Biol 2009; 29: 4788-4797.
30. Galigniana M. Steroid receptor coupling becomes nuclear. Chem Biol 2012; 19: 662-663.
31. Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids 2011; 76: 834-839.
32. Lemarié CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 2008; 86: 673-678.
33. Lemarié CA, Simeone SM, Nikonova A, Ebrahimian T, Deschênes ME, Coffman TM, et al. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 2011; 105: 852-859.
34. Di Zhang A, Nguyen Dinh Cat A, Soukaseum C, Escoubet B, Cherfa A, Messaoudi S, et al. Cross-talk between mineralocorticoid and an-giotensin II signaling for cardiac remodeling. Hypertension 2008; 52: 1060-1067.
35. Masaad C, Houard N, Lombes M, Barouki R. Modulation of human mineralocirticoid receptor function by protein kinase A. Mol Endo-crinol 1999; 13: 57-65.
36. Funder JW. Is aldosterone bad for the heart? Trends Endocrinol Metab 2004; 15: 139-142.
37. Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer 2006; 6: 459-471.
38. Wang RA, Mazumdar A, Vadlamudi RK, Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J 2002; 21: 5437-5447.
39. Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP, et al. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci 2006; 9: 234-242.
40. Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 2011; 121: 3233-3243.